Streetbeat News

OZEM

Roundhill ETF Trust

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Eli Lilly and Novo Nordisk faced significant stock declines as new competitors entered the weight-loss drug market. Pfizer and Roche announced advancements in obesity treatments, challenging the duopoly of Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The Tema GLP-1, Obesity and Cardiometabolic ETF (HRTS) fund reflects a diversified approach, investing in emerging GLP-1 players like Amgen, Terns Pharmaceuticals, and Viking Therapeutics.

Portfolio Pulse from Piero Cingari

July 18, 2024 | 8:59 pm

ETFs focused on weight-loss drugs, such as Roundhill GLP-1 Weight Loss ETF (OZEM) and Amplify Weight Loss Drug and Treatment ETF (THNR), have launched, heavily investing in Eli Lilly (LLY) and Novo Nordisk (NVO). While these drugs show promise, industry experts caution about long-term prospects and potential competition from new drugs.

Portfolio Pulse from Vandana Singh

June 07, 2024 | 2:42 pm

The newly launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction due to its significant holdings in Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO), which make up over 40% of its portfolio. These companies are leaders in the weight-loss drug market, with innovative treatments like Eli Lilly's Zepbound and Novo Nordisk's amycretin. OZEM offers a focused investment opportunity in this growing sector but comes with risks typical of niche investments.

Portfolio Pulse from Surbhi Jain

May 30, 2024 | 7:36 pm

The animated comedy 'South Park' will tackle weight-loss drugs in its upcoming special 'South Park: The End of Obesity,' premiering on May 24 on Paramount+. The special could put weight-loss drugs in a negative light, potentially impacting stocks like Novo Nordisk (NVO), Eli Lilly (LLY), and the Roundhill GLP-1 & Weight Loss ETF (OZEM).

Portfolio Pulse from Chris Katje

May 23, 2024 | 11:02 pm

Roundhill Investments has launched the Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM), the world's first ETF focused on GLP-1 weight loss drugs. The ETF includes significant holdings in Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO), which dominate the weight loss drug market. The market for these drugs is expected to grow significantly, potentially reaching $100 billion by 2030. Other companies like Amgen (NASDAQ:AMGN) and Viking Therapeutics (NASDAQ:VKTX) are also developing promising weight loss treatments.

Portfolio Pulse from Piero Cingari

May 21, 2024 | 8:33 pm

Roundhill Investments has launched the Roundhill GLP-1 & Weight Loss ETF (OZEM), which focuses on the growing weight loss management market. The ETF began trading on Nasdaq and targets the GLP-1 receptor agonists and weight management drugs sector.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 1:42 pm

Roundhill Investments CEO Dave Mazza discussed the potential short-lived nature of the current meme stock rally, driven by renewed interest in stocks like GameStop (GME) and AMC Entertainment (AMC). The MEME ETF was closed in November 2023 due to low assets and trading volume. Roundhill's other ETFs, including MAGS and CHAT, are performing well, with significant holdings in major tech companies. A new ETF focused on weight-loss drugs is also in the pipeline.

Portfolio Pulse from Chris Katje

May 17, 2024 | 7:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.